Hershey Medical Center Research Trials: September 2024 (Liver Center)

Research StudiesSeladelparPBC
Written By Wilson Jackson

AMPED

The purpose of this trial is to test different levels of exercise needed to reduce liver fat in patients with NASH.

Key inclusion:

  • Diagnosed with a severe form of nonalcoholic fatty liver disease known as nonalcoholic steatohepatitis and have a liver biopsy proving NASH within six months of enrollment

  • Be age 18 to 69

Study contact:

Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial

This phase 2 trial will assess the safety and efficacy of three doses of NNC0194-0499 in combination with semaglutide versus placebo in the treatment of NASH.

Key inclusion:

  • Diagnosed with a severe form of nonalcoholic fatty liver disease known as nonalcoholic steatohepatitis

  • Be ages 18 and older

Study contact:

EL-FIT NASH

This study will be a pilot study to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously confirmed in patients with cirrhosis,(1) in patients with Nonalcoholic Steatohepatitis (NASH)

Key inclusion:

  • Be ages 18 years or older

  • Have been diagnosed with nonalcoholic fatty liver disease (NAFLD)

  • Have a smart phone and fitness watch

Study contact:

ESSENCE

Nonalcoholic Steatohepatitis (NASH) is associated with increased risk of mortality. Currently, there are few treatment options. Therefore, there is a need for an effective and safe medication treatment options. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), can address certain aspects of NASH and is therefore considered a strong candidate for the treatment of NASH.

Key inclusion:

  • Be diagnosed with nonalcoholic steatohepatitis

  • Be ages 18 and older

Study contact:

KOWA NASH

This phase 2 trial will assess efficacy and safety of K-001 once daily K-877-ER 0.4 mg QD, and CSG452 20 mg QD in subjects with noncirrhotic NASH with liver fibrosis.

Key inclusion:

  • Be diagnosed with nonalcoholic steatohepatitis

  • Be ages 18 and older

Study contact:

NAVIGATE

This trial will evaluate the efficacy of belapectin in preventing the development of esophageal varices in NASH cirrhosis patients.

Key inclusion:

  • Be diagnosed with nonalcoholic steatohepatitis

  • Be ages 18 to 75

  • Be diagnosed with early stage cirrhosis

  • Be diagnosed with portal hypertension

Study contact:

A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis

Key inclusion:

  • Diagnosed with a severe form of nonalcoholic fatty liver disease known as nonalcoholic steatohepatitis

  • Ages 18 and older

Study contact:

A Phase 2A, Double-blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Magnesium 4 mg Tablets for Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Women With Polycystic Ovary Syndrome (PCOS)

Key inclusion:

  • Female

  • Ages 18 years or older

  • Diagnosed with nonalcoholic fatty liver disease (NAFLD) & Polycystic ovary syndrome (PCOS)

Study contact:

More nonalcoholic steatohepatitis (NASH) research studies

Additional studies are under review and will be accepting participants soon. Adults 18 and older with a diagnosis of nonalcoholic steatohepatitis (NASH) may be eligible.

Contact the study team to learn more:

Study contact:

Wilson Jackson
Previous

SRG Clinical Trials: November 2024
Next

Hershey Medical Center Research Trials: September 2024 (IBD, EOE, and Celiac)